Quick answer
What is Mazdutide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Mazdutide is a peptide, grouped on this site under Incretin receptor agonists, and the 12 research records kept here are 1 from a study in rats or mice, 6 from trials in people and 5 that do not state what kind of study it is.
The literature search returned 58 records. This site keeps 12 of them, which is 21 per cent of what came back.
What it is
This site puts it in the Incretin receptor agonists group.
A GLP-1 receptor and glucagon receptor dual agonist, per the retrieved records.[1, 2]
Stated in the titles of the cited 2022 EClinicalMedicine and 2022 Nature Communications papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 6 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 46 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine (2022). pmid:36247927
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature communications (2022). pmid:35750681